Environment-mediated drug resistance: a major contributor to minimal residual disease (original) (raw)

• Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658–1667 (1999).
  Article CAS PubMed Google Scholar
• Meads, M. B., Hazlehurst, L. A. & Dalton, W. S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 14, 2519–2526 (2008).
  Article CAS PubMed Google Scholar
• Cordes, N., Seidler, J., Durzok, R., Geinitz, H. & Brakebusch, C. β1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 25, 1378–1390 (2006).
  Article CAS PubMed Google Scholar
• Hazlehurst, L. A., Argilagos, R. F. & Dalton, W. S. β1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br. J. Haematol. 136, 269–275 (2007).
  Article CAS PubMed Google Scholar
• Shain, K. H., Landowski, T. H. & Dalton, W. S. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 168, 2544–2553 (2002).
  Article CAS PubMed Google Scholar
• Lwin, T. et al. Cell adhesion induces p27_Kip1_-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 110, 1631–1638 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Bidard, F. C. et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin. Cancer Res. 14, 3306–3311 (2008).
  Article CAS PubMed Google Scholar
• Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793–802 (2005).
  Article CAS PubMed Google Scholar
• Braun, S. et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J. Clin. Oncol. 18, 80–86 (2000).
  Article CAS PubMed Google Scholar
• Wiedswang, G. et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin. Cancer Res. 10, 5342–5348 (2004).
  Article Google Scholar
• Matsunaga, T. et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nature Med. 9, 1158–1165 (2003).
  Article CAS PubMed Google Scholar
• Bellamy, W. T., Dalton, W. S., Gleason, M. C., Grogan, T. M. & Trent, J. M. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res. 51, 995–1002 (1991).
  CAS PubMed Google Scholar
• Hazlehurst, L. A. et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 63, 7900–7906 (2003).
  CAS PubMed Google Scholar
• Teicher, B. A. et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247, 1457–1461 (1990).
  Article CAS PubMed Google Scholar
• Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 63, 1727–1733 (1979).
  CAS PubMed Google Scholar
• Feller, N. et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18, 1380–1390 (2004).
  Article CAS PubMed Google Scholar
• Hess, C. J. et al. Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method. Leukemia 18, 1981–1988 (2004).
  Article CAS PubMed Google Scholar
• Brisco, J. et al. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 87, 5251–5256 (1996).
  Article CAS PubMed Google Scholar
• Heiss, M. M. et al. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J. Clin. Oncol. 20, 2005–2016 (2002).
  Article CAS PubMed Google Scholar
• Campana, D. Status of minimal residual disease testing in childhood haematological malignancies. Br. J. Haematol. 143, 481–489 (2008).
  PubMed PubMed Central Google Scholar
• Pui, C. H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166–178 (2006).
  Article CAS PubMed Google Scholar
• Matsunaga, T. et al. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 22, 353–360 (2008).
  Article CAS PubMed Google Scholar
• Becker, P. S. et al. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 113, 866–874 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• de la Fuente, M. T. et al. Involvement of p53 in α4β1 integrin-mediated resistance of B-CLL cells to fludarabine. Biochem. Biophys. Res. Commun. 311, 708–712 (2003).
  Article CAS PubMed Google Scholar
• Folgiero, V. et al. Induction of ErbB-3 expression by α6β4 integrin contributes to tamoxifen resistance in ERβ1-negative breast carcinomas. PLoS ONE 3, e1592 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Yao, E. S. et al. Increased β1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 67, 659–664 (2007).
  Article CAS PubMed Google Scholar
• Oshita, F. et al. Increased expression of integrin β1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res. 22, 1065–1070 (2002).
  CAS PubMed Google Scholar
• Graf, M. et al. Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis. Am. J. Hematol. 81, 227–235 (2006).
  Article CAS PubMed Google Scholar
• Vuoristo, M. et al. Increased gene expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma. Melanoma Res. 17, 215–223 (2007).
  Article CAS PubMed Google Scholar
• Nikkola, J. et al. Integrin chains β1 and αv as prognostic factors in human metastatic melanoma. Melanoma Res. 14, 29–37 (2004).
  Article CAS PubMed Google Scholar
• Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Med. 5, 662–668 (1999).
  Article CAS PubMed Google Scholar
• Sherman-Baust, C. A. et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3, 377–386 (2003).
  Article CAS PubMed Google Scholar
• Recher, C. et al. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res. 64, 3191–3197 (2004).
  Article CAS PubMed Google Scholar
• Cario, G. et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 105, 821–826 (2005).
  Article CAS PubMed Google Scholar
• Flotho, C. et al. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 108, 1050–1057 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• van Stijn, A. et al. Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis. Clin. Cancer Res. 11, 2540–2546 (2005).
  Article CAS PubMed Google Scholar
• Flotho, C. et al. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood 110, 1271–1277 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Tlsty, T. D. & Coussens, L. M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1, 119–150 (2006).
  Article CAS PubMed Google Scholar
• Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nature Med. 14, 518–527 (2008).
  Article CAS PubMed Google Scholar
• Hawsawi, N. M. et al. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res. 68, 2717–2725 (2008).
  Article CAS PubMed Google Scholar
• Ohuchida, K. et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res. 64, 3215–3222 (2004).
  Article CAS PubMed Google Scholar
• Polyak, K., Haviv, I. & Campbell, I. G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 25, 30–38 (2009).
  Article CAS PubMed Google Scholar
• Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313–2323 (2008).
  Article CAS PubMed Google Scholar
• Fridman, R. et al. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc. Natl Acad. Sci. USA 87, 6698–6702 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Mori, Y. et al. Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104, 2149–2154 (2004).
  Article CAS PubMed Google Scholar
• Park, C. C. et al. β1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 66, 1526–1535 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J. & Bissell, M. J. β1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 68, 4398–4405 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J. & Dalton, W. S. Adhesion to fibronectin via β1 integrins regulates p27_kip1_ levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19, 4319–4327 (2000).
  Article CAS PubMed Google Scholar
• Fu, Y. et al. Overexpression of integrin β1 inhibits proliferation of hepatocellular carcinoma cell SMMC-7721 through preventing Skp2-dependent degradation of p27 via PI3K pathway. J. Cell Biochem. 102, 704–718 (2007).
  Article CAS PubMed Google Scholar
• Hartmann, T. N., Burger, J. A., Glodek, A., Fujii, N. & Burger, M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24, 4462–4471 (2005).
  Article CAS PubMed Google Scholar
• Hodkinson, P. S. et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 13, 1776–1788 (2006).
  Article CAS PubMed Google Scholar
• Hoyt, D. G. et al. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res. 56, 4146–4149 (1996).
  CAS PubMed Google Scholar
• Nefedova, Y., Landowski, T. H. & Dalton, W. S. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17, 1175–1182 (2003).
  Article CAS PubMed Google Scholar
• Borsellino, N. et al. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85, 134–144 (1999).
  Article CAS PubMed Google Scholar
• Catlett-Falcone, R. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105–115 (1999).
  Article CAS PubMed Google Scholar
• Duan, Z. et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin. Cancer Res. 12, 5055–5063 (2006).
  Article CAS PubMed Google Scholar
• Frassanito, M. A., Cusmai, A., Iodice, G. & Dammacco, F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97, 483–489 (2001).
  Article CAS PubMed Google Scholar
• Perez, L. E. et al. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J. Immunol. 180, 1545–1555 (2008).
  Article CAS PubMed Google Scholar
• Voorhees, P. M. et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin. Cancer Res. 13, 6469–6478 (2007).
  Article CAS PubMed Google Scholar
• Allinen, M. et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6, 17–32 (2004).
  Article CAS PubMed Google Scholar
• Arnulf, B. et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21, 158–163 (2007).
  Article CAS PubMed Google Scholar
• Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348 (2005).
  Article CAS PubMed Google Scholar
• Sanz-Rodriguez, F., Hidalgo, A. & Teixido, J. Chemokine stromal cell-derived factor-1α modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 97, 346–351 (2001).
  Article CAS PubMed Google Scholar
• Kettritz, R., Choi, M., Rolle, S., Wellner, M. & Luft, F. C. Integrins and cytokines activate nuclear transcription factor-κB in human neutrophils. J. Biol. Chem. 279, 2657–2665 (2004).
  Article CAS PubMed Google Scholar
• Shain, K. H. et al. β1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 69, 1009–1015 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Tancred, T. M., Belch, A. R., Reiman, T., Pilarski, L. M. & Kirshner, J. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J. Histochem. Cytochem. 57, 239–247 (2008).
  Article PubMed CAS Google Scholar
• White, D. E. et al. Addressing the role of cell adhesion in tumor cell dormancy. Cell Cycle 5, 1756–1759 (2006).
  Article CAS PubMed Google Scholar
• St. Croix, B. et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nature Med. 2, 1204–1210 (1996).
  Article Google Scholar
• St. Croix, B. et al. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl Cancer Inst. 88, 1285–1296 (1996).
  Article CAS Google Scholar
• White, D. E. et al. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6, 159–170 (2004).
  Article CAS PubMed Google Scholar
• Weaver, V. M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231–245 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Goodison, S. et al. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin. Cancer Res. 9, 3808–3814 (2003).
  CAS PubMed Google Scholar
• Naumov, G. N. et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 62, 2162–2168 (2002).
  CAS PubMed Google Scholar
• Pantel, K. et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J. Natl Cancer Inst. 85, 1419–1424 (1993).
  Article CAS PubMed Google Scholar
• Gong, J., Ko, T. C. & Brattain, M. G. Disruption of fibronectin binding to the α5β1 integrin stimulates the expression of cyclin-dependent kinases and DNA synthesis through activation of extracellular signal-regulated kinase. J. Biol. Chem. 273, 1662–1669 (1998).
  Article CAS PubMed Google Scholar
• Fischer, C. et al. Galectin-1 interacts with the α5β1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J. Biol. Chem. 280, 37266–37277 (2005).
  Article CAS PubMed Google Scholar
• Henriet, P., Zhong, Z. D., Brooks, P. C., Weinberg, K. I. & DeClerck, Y. A. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc. Natl Acad. Sci. USA 97, 10026–10031 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Nefedova, Y., Cheng, P., Alsina, M., Dalton, W. S. & Gabrilovich, D. I. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 103, 3503–3510 (2004).
  Article CAS PubMed Google Scholar
• Bisping, G. et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 101, 2775–2783 (2003).
  Article CAS PubMed Google Scholar
• Dankbar, B. et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor–stromal cell interactions in multiple myeloma. Blood 95, 2630–2636 (2000).
  Article CAS PubMed Google Scholar
• Stupp, R. & Ruegg, C. Integrin inhibitors reaching the clinic. J. Clin. Oncol. 25, 1637–1638 (2007).
  Article CAS PubMed Google Scholar
• Cianfrocca, M. E. et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer 94, 1621–1626 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• McNeel, D. G. et al. Phase I trial of a monoclonal antibody specific for αvβ3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res. 11, 7851–7860 (2005).
  Article CAS PubMed Google Scholar
• Mullamitha, S. A. et al. Phase I evaluation of a fully human anti-αv integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res. 13, 2128–2135 (2007).
  Article CAS PubMed Google Scholar
• Reardon, D. A. et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26, 5610–5617 (2008).
  Article CAS PubMed Google Scholar
• Sondergaard, T. E. et al. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol. Oncol. 27, 17–22 (2009).
  Article CAS PubMed Google Scholar
• Weitz-Schmidt, G. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med. 7, 687–692 (2001).
  Article CAS PubMed Google Scholar
• Weitz-Schmidt, G., Welzenbach, K., Dawson, J. & Kallen, J. Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo. J. Biol. Chem. 279, 46764–46771 (2004).
  Article CAS PubMed Google Scholar
• Denoyelle, C. et al. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on agressive human breast cancer cells. Cell Signal 15, 327–338 (2003)
  Article CAS PubMed Google Scholar
• Schmidmaier, R. et al. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104, 1825–1832 (2004).
  Article CAS PubMed Google Scholar
• Kinbara, K., Goldfinger, L. E., Hansen, M., Chou, F. L. & Ginsberg, M. H. Ras GTPases: integrins' friends or foes? Nature Rev. Mol. Cell Biol. 4, 767–776 (2003).
  Article CAS Google Scholar
• Azab, A. K. et al. Rho-A and Rac-1 GTPases play major and differential roles in SDF1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 114, 619–629 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Schmidmaier, R. et al. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur. J. Haematol. 79, 240–243 (2007).
  Article CAS PubMed Google Scholar
• Maeda, T., Kawane, T. & Horiuchi, N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 144, 681–692 (2003).
  Article CAS PubMed Google Scholar
• Mundy, G. et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946–1949 (1999).
  Article CAS PubMed Google Scholar
• Landowski, T. H., Olashaw, N. E., Agrawal, D. & Dalton, W. S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells. Oncogene 22, 2417–2421 (2003).
  Article CAS PubMed Google Scholar
• San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906–917 (2008).
  Article CAS PubMed Google Scholar
• Lin, B. et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 62, 5019–5026 (2002).
  CAS PubMed Google Scholar
• Bisping, G. et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Clin. Cancer Res. 15, 520–531 (2009).
  Article CAS PubMed Google Scholar
• Burger, M. et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106, 1824–1830 (2005).
  Article CAS PubMed Google Scholar
• Zeng, Z. et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215–6224 (2008).
  Article PubMed CAS Google Scholar
• Goldie, J. H. & Coldman, A. J. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat. Rep. 67, 923–931 (1983).
  CAS PubMed Google Scholar
• Hazlehurst, L. A. et al. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res 66, 2338–2345 (2006).
  Article CAS PubMed Google Scholar
• Moshaver, B. et al. Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival. Leuk. Lymphoma 49, 134–148 (2008).
  Article CAS PubMed Google Scholar
• Spiotto, M. T., Rowley, D. A. & Schreiber, H. Bystander elimination of antigen loss variants in established tumors. Nature Med. 10, 294–298 (2004).
  Article CAS PubMed Google Scholar
• Zhang, B. et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204, 49–55 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, B. et al. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 68, 1563–1571 (2008).
  Article CAS PubMed Google Scholar
• Kirshner, J. et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 112, 2935–2945 (2008).
  Article CAS PubMed Google Scholar